Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,218.00
(
1.73%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
98.37
(
1.71%
)
Bitcoin
77,883.70
(
-0.45%
)
News Focus
News Focus
Post# of 890
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

masterlongevity

Send PM Follow Ignore
Followers 24
Posts 2597
Boards Moderated 0
Alias Born 01/07/2004

masterlongevity

Re: None

Friday, 12/21/2007 4:25:47 PM

Friday, December 21, 2007 4:25:47 PM

Post# of 890
Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer's Disease
http://biz.yahoo.com/bw/071221/20071221005747.html?.v=1




Elan and Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
http://biz.yahoo.com/bw/071221/20071221005705.html?.v=1
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote